Landmark approval for Vertex's CRISPR drug 2 steps closer after trial wins, PDUFA date granted

Vertex and CRISPR Therapeutics’ dream of getting the first-ever CRISPR gene editing therapy approved now seems within reach as the candidate aced primary endpoints in a pair of phase 3 trials mere hours after the FDA penciled in a decision date for December.